Clinical trial
Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes
NCT05694715 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 23, 2023
- Completion date
- January 31, 2028
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atm gene mutation, brca1 mutation, brca2 mutation, metastatic solid tumor, palb2 gene mutation